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Introduction {#acn351007-sec-0001}
============

ERLIN2 (ER lipid raft‐associated 2) is an endoplasmic reticulum protein that mediates intracellular calcium signaling through its action on inositol 1,4,5‐trisphosphate receptors, making it an important regulator of several cellular processes important for neurodevelopment and neurotransmission.[1](#acn351007-bib-0001){ref-type="ref"}, [2](#acn351007-bib-0002){ref-type="ref"}, [3](#acn351007-bib-0003){ref-type="ref"}

Defects in *ERLIN2* are a known cause of several neurodegenerative conditions. Biallelic pathogenic variants in *ERLIN2* are responsible for autosomal‐recessive hereditary spastic paraplegia (HSP) 18 (SPG18; MIM 611225), a progressive disorder characterized by intellectual disability (ID), multiple joint contractures, and gradual development of spasticity and weakness primarily affecting the lower extremities. Affected individuals often present during infancy or childhood with delayed motor milestones and loss of motor abilities.[4](#acn351007-bib-0004){ref-type="ref"} Recently, an autosomal‐dominant form was described in two unrelated families with affected members carrying the same heterozygous missense variant in *ERLIN2* (c.386G\> C; p.Ser129Thr).[5](#acn351007-bib-0005){ref-type="ref"} Finally, a homozygous splice junction variant causing reduced *ERLIN2* transcript was the cause of juvenile primary lateral sclerosis in a consanguineous family with several members affected by language regression, pseudobulbar palsy, reduced muscle bulk, distal greater than proximal weakness, and kyphosis/scoliosis.[6](#acn351007-bib-0006){ref-type="ref"}

In this report, we expand the clinical and genetic spectra of *ERLIN2‐*related disorders by presenting five individuals from four different families with varying presentations of developmental regression, spasticity, motor impairment, and in one case, epileptic seizures. Three families (four affected individuals) demonstrate autosomal‐recessive inheritance with biallelic variants, whereas the fifth affected individual has a heterozygous de novo variant consistent with an autosomal‐dominant form of *ERLIN2*‐related disorder.

Patients and Methods {#acn351007-sec-0002}
====================

Participants in this study underwent clinical evaluations at Boston Children's Hospital, Kennedy Krieger Institute, IRCCS Fondazione Stella Maris, and IRCCS Istituto delle Scienze Neurologiche di Bologna. Two participants underwent clinical whole exome sequencing through GeneDx, and three participants had multigene panel testing using methodologies and a bioinformatic pipelines already reported elsewhere.[7](#acn351007-bib-0007){ref-type="ref"} No other pathogenic or likely pathogenic variants were identified that would explain the clinical presentation.

Results {#acn351007-sec-0003}
=======

Demographic and genetic features {#acn351007-sec-0004}
--------------------------------

The five individuals (two males and three females) in this cohort had heterogenous demographic, clinical, and genetic characteristics (Table [1](#acn351007-tbl-0001){ref-type="table"}, Table [S1](#acn351007-sup-0001){ref-type="supplementary-material"}). The age at last follow‐up ranged from 3 to 51 years, and two were male. Three individuals were of South Asian descent (Pakistan and Sri Lanka), one case was from Italy, and one case was of Ghanese descent.

###### 

Clinical features of the patients in our cohort.

                                            Patient 1                                                          Patient 2                                                                                             Patient 3                                                                                        Patient 4 (sister of Patient 3)                                                                  Patient 5
  ----------------------------------------- ------------------------------------------------------------------ ----------------------------------------------------------------------------------------------------- ------------------------------------------------------------------------------------------------ ------------------------------------------------------------------------------------------------ ----------------------------------
  Sex/Age at last exam                      Male/12 years                                                      Female/10 years                                                                                       Male/9 years                                                                                     Female/3 years                                                                                   Female/51 years
  Genetics                                                                                                                                                                                                                                                                                                                                                                                                             
  Inheritance/Consanguinity                 Recessive (parents are carriers)/Yes (parents are first cousins)   Mother heterozygous/No                                                                                Recessive (parents are carriers)/Yes (parents are second cousins)                                Recessive (parents are carriers)/No                                                              de novo/No
  Accession number                          NM_007175.6                                                        NM_007175.6                                                                                           NM_007175.6                                                                                      NM_007175.6                                                                                      NM_007175.6
  cDNA change                               c.861_874dup14                                                     c.407T\> G                                                                                            c.861_874dup14                                                                                   c.861_874dup14                                                                                   c.187C\> A
  Protein change                            p.Asn292ArgfsX26                                                   p.Val136Gly                                                                                           p.Asn292ArgfsX26                                                                                 p.Asn292ArgfsX26                                                                                 p.Gln63Lys
  Zygosity                                  Homozygous                                                         Homozygous due to maternal uniparental isodisomy of chromosome 8                                      Homozygous                                                                                       Homozygous                                                                                       Heterozygous
  Found in gnomAD                           No                                                                 No                                                                                                    No                                                                                               No                                                                                               No
  Variant detected by                       Clinical exome sequencing                                          Clinical exome sequencing                                                                             Targeted gene panel                                                                              Targeted gene panel                                                                              Targeted gene panel
  Previously reported?                      No                                                                 Yes (previously reported with limited clinical information[1](#acn351007-bib-0001){ref-type="ref"})   Yes (previously reported with no clinical information[2](#acn351007-bib-0002){ref-type="ref"})   Yes (previously reported with no clinical information[2](#acn351007-bib-0002){ref-type="ref"})   No
  Growth parameters at last exam                                                                                                                                                                                                                                                                                                                                                                                       
  Head circumference                        Normal                                                             Normal                                                                                                Normal                                                                                           Normal                                                                                           Normal
  Weight                                    z‐score −0.27                                                      z‐score −1.09                                                                                         not available                                                                                    not available                                                                                    not available
  Height                                    z‐score −1.46                                                      z‐score −0.87                                                                                         not available                                                                                    not available                                                                                    not available
  Symptom Onset                                                                                                                                                                                                                                                                                                                                                                                                        
  Age of onset                              8 months                                                           2 years                                                                                               2 years                                                                                          10 months                                                                                        32 years
  Initial symptoms                          Motor delay, spastic diplegia                                      Motor delay, spastic diplegia                                                                         Motor delay                                                                                      Motor delay                                                                                      Spastic diplegia, wide base gait
  Developmental regression (age of onset)   Yes (5 years)                                                      Yes (unknown)                                                                                         Yes (2 years)                                                                                    Yes (1 year)                                                                                     No
  Nature of regression                      Lost ability to crawl and climb steps                              Lost ability to independent walking, worsening dysarthria                                             Lost ability to walk independently                                                               Loss of standing position                                                                        No
  Current motor abilities                   Able to pull to stand, cruise, walk with posterior walker          Requires wheelchair                                                                                   Able to stand, crawl, and walk with bilateral assistance                                         Unable to walk                                                                                   Requires cane to walk
  Language and cognition                                                                                                                                                                                                                                                                                                                                                                                               
  Current language abilities                200 + words, phrases                                               Age appropriate comprehension but difficulty speaking, hypophonia, difficulty opening mouth           Limited speech                                                                                   Absent speech                                                                                    Dysarthric speech
  Intellectual disability                   Yes                                                                No                                                                                                    Yes (mild‐moderate)                                                                              Yes                                                                                              No
  Behavioral dysregulation                  No                                                                 No                                                                                                    No                                                                                               No                                                                                               No
  Motor                                                                                                                                                                                                                                                                                                                                                                                                                
  HSP phenotype                             Complex                                                            Pure                                                                                                  Complex                                                                                          Complex                                                                                          Pure
  Axial hypotonia                           Yes                                                                No                                                                                                    Yes                                                                                              Yes                                                                                              No
  Appendicular spasticity                   Yes                                                                Yes (spastic quadriplegia)                                                                            Yes                                                                                              Yes                                                                                              Yes
  Motor impairment                          Lower\> upper limbs                                                Lower\> upper limbs                                                                                   Lower\>\> upper limbs                                                                            Lower\>\>upper limbs                                                                             Lower limbs
  Dystonia                                  Yes (upper limbs)                                                  Yes (hands and lower limbs)                                                                           Yes (hands, fluctuating)                                                                         No                                                                                               No
  Pyramidal tract signs                     All limbs                                                          All limbs                                                                                             All limbs                                                                                        All limbs                                                                                        Lower\> upper limbs
  Tremor                                    No                                                                 No                                                                                                    Yes (occasional, hands)                                                                          No                                                                                               No
  Dysmetria                                 No                                                                 No                                                                                                    Yes (mild)                                                                                       No                                                                                               Yes
  Gait pattern                              Spastic gait (scissoring gait)                                     Spastic gait (scissoring gait, able to take few steps)                                                Spastic gait (scissoring gait with support)                                                      Crawling                                                                                         Spastic, ataxic gait
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The types of *ERLIN2* alterations represented in this cohort included a common homozygous frameshift variant found in two unrelated consanguineous families (p.Asn292ArgfsX26) and a de novo heterozygous missense variant (p.Gln63Lys) (Figure [1](#acn351007-fig-0001){ref-type="fig"}). The remaining individual was homozygous for a c.407T\> G variant (p.Val136Gly) due to maternal uniparental isodisomy (UPD) of chromosome 8, with the unaffected mother heterozygous for this variant. Evidence for pathogenicity of the missense variants derives from scores in multiple in silico prediction tools and a high evolutionary conservation of mutated residues across species (see Figure [1](#acn351007-fig-0001){ref-type="fig"}).

![Pedigrees for all affected patients, multiple sequence alignment, and evidence of pathogenicity for the missense variants. In pedigrees, arrows denote probands; squares represent males and circles represent females; dotted circles/squares denote heterozygous carriers; M denotes the presence of an *ERLIN2* variant on one allele; hyphen denotes the presence of wild‐type allele. We used the following pathogenicity prediction tools: MutationTaster (<http://www.mutationtaster.org/>), Functional Analysis through Hidden Markov Models (FATHMM);[22](#acn351007-bib-0022){ref-type="ref"} Sorting Intolerant From Tolerant (SIFT);[23](#acn351007-bib-0023){ref-type="ref"} Protein Variation Effect Analyzer (PROVEAN);[24](#acn351007-bib-0024){ref-type="ref"} PolyPhen‐2;[25](#acn351007-bib-0025){ref-type="ref"} UMD‐Predictor;[26](#acn351007-bib-0026){ref-type="ref"} Genomic Evolutionary Rate Profiling (GERP);[27](#acn351007-bib-0027){ref-type="ref"} and Combined Annotation Dependent Depletion (CADD).[28](#acn351007-bib-0028){ref-type="ref"}](ACN3-7-573-g001){#acn351007-fig-0001}

The three different *ERLIN2* variants found in the five participants in our cohort are likely pathogenic changes. Patient 1, patient 3, and patient 4 harbored the same homozygous frameshift variants expected to cause loss of function, a known mechanism of disease for *ERLIN2*‐related disorders, although this was not proved at the cDNA level. The missense variants identified in patient 2 and patient 5 were novel but several lines of evidence support that they are disease‐causing. The variants are absent in large population databases (ExAC, 1000 Genomes) and predicted to be deleterious by in silico tools (CADD scores\> 23).

Symptom onset {#acn351007-sec-0005}
-------------

Age of onset of motor delay and/or spasticity spanned infancy/early childhood in the four individuals with homozygous *ERLIN2* variants to adulthood in one individual with heterozygous de novo missense. Developmental regression was notable in three patients (patient 1, patient 2, patient 3), characterized by loss of ambulatory abilities. In patient 1, regression occurred at age 5 years, when he lost the ability to crawl and climb steps. Patient 2 had motor delay and spastic diplegia noted around age 2 years, after which she developed progressive motor deterioration, losing the ability to walk with a walker and requiring a wheelchair for mobility. Patient 3 had loss of ambulation after age 2 years.

Language, cognition, and epilepsy {#acn351007-sec-0006}
---------------------------------

ID was present in the three participants with the homozygous *ERLIN2* frameshift variants and absent in the two participants with the *ERLIN2* missense variants. Among those without ID, dysarthria and hypophonia were the noted speech difficulties. Patient 1 has sensorineural hearing loss, which has not been previously reported in association with *ERLIN2*‐related disorders. One patient presented with generalized myoclonic absence seizures at the age of 2 years, which stopped after treatment with valproate.

Motor phenotype {#acn351007-sec-0007}
---------------

The primary motor phenotype of the participants was axial hypotonia and appendicular spasticity. In four patients, spasticity affected lower extremities greater than upper extremities, and in the remaining individual, spasticity was limited to the lower extremities. More than half (3/5) of the cohort had dystonia. Patient 1 had intermittent dystonia affecting his arms. Patient 2 also had intermittent dystonic posturing affecting her arms and legs. Patient 1 and 2 did not undergo empiric carbidopa/levodopa trial. Hyperreflexia and predominantly lower extremity weakness were present in all five individuals. Patient 4 could crawl but not walk; the other four individuals had a spastic gait, with superimposed cerebellar features (tremor or dysmetria) in two individuals.

Neuroimaging features {#acn351007-sec-0008}
---------------------

Neuroimaging findings were variable. Thinning of the corpus callosum and other white matter changes were the primary abnormalities in two cases. Two individuals had a normal brain MRI. Patient 1 had arachnoid cyst that was fenestrated without any clinical improvement.

Discussion {#acn351007-sec-0009}
==========

The patients in our cohort constitute a wide spectrum of phenotypes consistent with previous reports of *ERLIN2*‐related disorders (Table [S2](#acn351007-sup-0002){ref-type="supplementary-material"}). There appear to be three clinical phenotypes associated with *ERLIN2* defects: pure HSP, complex HSP, and juvenile primary lateral sclerosis. The first two phenotypes are equally represented in the five participants from this study, who demonstrated progressive spasticity, weakness, and gait disturbance, with age of onset ranging from infancy to adulthood.

One of the novel clinical features seen in association with *ERLIN2*‐related disorders is sensorineural hearing loss (seen in patient 1). This patient did not have any pathogenic variants detected in mtDNA sequencing, and no other variants were reported on clinical exome sequencing to suggest an alternative cause for the hearing loss. Thus, hearing loss may be an expansion of the clinical spectrum of *ERLIN2*‐related disorders, and individuals with a new diagnosis should consider undergoing audiological evaluation.

The variants discovered in our cohort expand the genetic landscape of *ERLIN2*‐related disorders. Four out of the five patients had alterations in *ERLIN2* that are previously unreported in association with the disorders (patient 2 is part of a prior report, but detailed clinical information about her in that report is limited[8](#acn351007-bib-0008){ref-type="ref"}; similar is the case for patients 3 and 4[7](#acn351007-bib-0007){ref-type="ref"}). In addition, patient 2 has a novel missense variant that is homozygous due to maternal UPD of chromosome 8, with her mother being a heterozygous carrier.

Four of the five patients in our study had homozygous variants, whereas patient 5 carried a de novo variant, confirming the recent report of an autosomal‐dominant form of *ERLIN2*‐related disorder. The vast majority of previous studies of *ERLIN2*‐related disorders have identified biallelic variants (Table [S2](#acn351007-sup-0002){ref-type="supplementary-material"}).[4](#acn351007-bib-0004){ref-type="ref"}, [6](#acn351007-bib-0006){ref-type="ref"}, [9](#acn351007-bib-0009){ref-type="ref"}, [10](#acn351007-bib-0010){ref-type="ref"}, [11](#acn351007-bib-0011){ref-type="ref"}, [12](#acn351007-bib-0012){ref-type="ref"} One report, however, identified a recurrent heterozygous missense variant (c.386G\> C; p.Ser129Thr) in multiple affected individuals from two large unrelated families.[5](#acn351007-bib-0005){ref-type="ref"} Overall, these data lend support to the notion that there are autosomal‐recessive and autosomal‐dominant forms of *ERLIN2*‐related disorders, similar to a small number of other genetic causes of HSP, such as defects in *ATL1* (SPG3A),[13](#acn351007-bib-0013){ref-type="ref"} *KIF1A* (SPG30),[14](#acn351007-bib-0014){ref-type="ref"} *KIF1C* (SPG58),[15](#acn351007-bib-0015){ref-type="ref"} *REEP1* (SPG31),[16](#acn351007-bib-0016){ref-type="ref"} and *SPG7* (SPG7).[17](#acn351007-bib-0017){ref-type="ref"}

Certain genotype‐phenotype correlations emerged within our cohort. The patient with the de novo heterozygous *ERLIN2* variant (patient 5) appeared less severely affected compared to the other participants with homozygous *ERLIN2* variants, as was shown by a later age of symptom onset, absence of developmental regression, and absence of ID. In fact, among prior reports of *ERLIN2*‐related disorders (Table 2), ID was absent in 5/6 unrelated individuals who had a missense *ERLIN2* variant on at least one allele (three families with affected individuals);[5](#acn351007-bib-0005){ref-type="ref"}, [11](#acn351007-bib-0011){ref-type="ref"}, [12](#acn351007-bib-0012){ref-type="ref"}, [18](#acn351007-bib-0018){ref-type="ref"}, [19](#acn351007-bib-0019){ref-type="ref"} conversely, ID was present in all individuals with a homozygous truncating variant.[4](#acn351007-bib-0004){ref-type="ref"}, [9](#acn351007-bib-0009){ref-type="ref"}, [20](#acn351007-bib-0020){ref-type="ref"}, [21](#acn351007-bib-0021){ref-type="ref"} This observation suggests that *ERLIN2*‐related disorders can present dosage‐dependent clinical features likely due to reduced protein function. It is worth noting that our data lend further support to the notion that zygosity is no longer a barrier to defining a molecular diagnosis in HSP, suggesting that even more HSP genes might be associated with different modes of inheritance. If this is truly the case, it would have implications for the estimated diagnostic yield and could imply differences in disease‐associated phenotypes. The question of why parental carriers of a single variant in *ERLIN2* are healthy, though harboring a heterozygous predictably pathogenic variant, remains unclear. It is possible that the *ERLIN2* missense variants causing disease in heterozygous state have different effect on protein, such as dominant‐negative or gain‐of‐function effects, whereas the variants that cause disease only when biallelic cause loss/reduction of protein function [5](#acn351007-bib-0005){ref-type="ref"}. This would need to be investigated with functional studies. A final comment worth mentioning is the maternal UPD seen in our report. This unusual modality of transmission should alert clinicians to carefully evaluate results of next‐generation gene sequencing when counseling families, especially on risks of recurrence.

In sum, we define new clinical presentations and gene variants in *ERLIN2*‐related pathology; we report a common pathogenic variant in families of South Asian ancestry; and we affirm that autosomal‐dominant transmission can be a mode of inheritance associated with *ERLIN2*‐related disorders. Further research is needed to elucidate disease mechanisms of *ERLIN2*‐related disorders.
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